Cingolani, Antonella
 Distribuzione geografica
Continente #
NA - Nord America 3.432
EU - Europa 2.905
AS - Asia 2.598
SA - Sud America 689
AF - Africa 120
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 7
Totale 9.776
Nazione #
US - Stati Uniti d'America 3.263
SG - Singapore 1.207
IT - Italia 643
CN - Cina 616
DE - Germania 594
BR - Brasile 584
SE - Svezia 499
FR - Francia 238
GB - Regno Unito 194
VN - Vietnam 154
IE - Irlanda 141
UA - Ucraina 137
FI - Finlandia 115
IN - India 100
CA - Canada 91
ID - Indonesia 90
PL - Polonia 80
RU - Federazione Russa 66
HK - Hong Kong 63
MX - Messico 51
TR - Turchia 47
AR - Argentina 45
NL - Olanda 42
BD - Bangladesh 40
AT - Austria 34
BE - Belgio 32
PK - Pakistan 30
JP - Giappone 29
IQ - Iraq 27
IR - Iran 26
SA - Arabia Saudita 26
KR - Corea 24
AU - Australia 23
ZA - Sudafrica 23
EG - Egitto 18
PH - Filippine 18
MA - Marocco 17
EC - Ecuador 13
KE - Kenya 13
TN - Tunisia 13
VE - Venezuela 13
ES - Italia 12
LT - Lituania 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
CI - Costa d'Avorio 11
JO - Giordania 11
MY - Malesia 11
UZ - Uzbekistan 11
CO - Colombia 9
CZ - Repubblica Ceca 9
IL - Israele 9
PT - Portogallo 8
CL - Cile 7
NG - Nigeria 7
NP - Nepal 7
PE - Perù 7
KG - Kirghizistan 6
CR - Costa Rica 5
EE - Estonia 5
GR - Grecia 5
PY - Paraguay 5
RO - Romania 5
AZ - Azerbaigian 4
BG - Bulgaria 4
EU - Europa 4
LV - Lettonia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
UY - Uruguay 4
BB - Barbados 3
BZ - Belize 3
KW - Kuwait 3
LB - Libano 3
MM - Myanmar 3
NO - Norvegia 3
OM - Oman 3
SD - Sudan 3
TH - Thailandia 3
AO - Angola 2
BW - Botswana 2
BY - Bielorussia 2
CM - Camerun 2
DZ - Algeria 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
JM - Giamaica 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MG - Madagascar 2
MO - Macao, regione amministrativa speciale della Cina 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
TJ - Tagikistan 2
VA - Santa Sede (Città del Vaticano) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
Totale 9.758
Città #
Singapore 542
Chandler 486
Ashburn 374
Rome 171
New York 168
Dublin 138
Beijing 115
Dallas 112
Jacksonville 90
Los Angeles 83
Jakarta 82
Milan 80
San Mateo 80
Hefei 74
Chicago 69
The Dalles 69
Nanjing 67
Ann Arbor 61
Wilmington 58
Hong Kong 56
São Paulo 55
Ho Chi Minh City 53
Boston 52
Munich 52
Redmond 51
Helsinki 47
Dearborn 46
Princeton 46
Kraków 45
Moscow 40
Frankfurt am Main 38
London 37
Hanoi 36
Bremen 34
Marseille 33
Boardman 32
North Bergen 32
Houston 31
Nuremberg 31
Brussels 28
Cattolica 28
Tokyo 26
Woodbridge 26
Kent 25
Nürnberg 24
Nanchang 23
Izmir 22
Amsterdam 21
Ottawa 21
Rio de Janeiro 21
Redwood City 20
Seoul 20
Turku 19
Warsaw 19
Atlanta 18
Buffalo 18
Lappeenranta 18
Lawrence 18
Montreal 18
Seattle 18
Fairfield 17
San Francisco 17
Düsseldorf 16
Lancaster 16
Phoenix 16
San Jose 16
Brooklyn 15
Guangzhou 15
Johannesburg 15
Kunming 15
Orem 15
Pune 15
Vienna 15
Denver 14
Norwalk 14
Poplar 14
Santa Clara 14
Stockholm 14
Dammam 13
Lahore 13
Mexico City 13
Augusta 12
Fremont 12
Tianjin 12
Abidjan 11
Amman 11
Baghdad 11
Belo Horizonte 11
Council Bluffs 11
Dhaka 11
Lauterbourg 11
Toronto 11
University Park 11
Washington 11
Wroclaw 11
Bexley 10
Cairo 10
Chennai 10
Kish 10
Mountain View 10
Totale 4.736
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 499
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 255
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 254
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 208
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 200
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 199
Health-related quality of life (HRQoL) from HIV patients’ perspective: comparison of patient-reported outcome (PRO) measures among people living with hiv (PLWH) and other chronic clinical conditions 196
Plasma levels of Interleukin-6 and Interleukin-10 in preterm neonates evaluated for sepsis 180
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 177
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 157
Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma 154
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 153
COVID-19 atypical Parsonage-Turner syndrome: a case report 147
Residual respiratory impairment after COVID-19 pneumonia 147
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 143
Malnutrition in COVID-19 survivors: prevalence and risk factors 142
Residual respiratory impairment after COVID-19 pneumonia 140
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 138
Sarilumab use in severe SARS-CoV-2 pneumonia 137
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 136
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 134
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 133
Cauda Equina Enhancing Lesion in an HIV-Infected Patient. Case Report and Literature Review. 131
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 130
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 123
Effect of Lockdowns on Hospital Staff in a COVID Center: A Retrospective Observational Study 121
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 121
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 120
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 117
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 117
Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital 117
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients 116
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 115
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 113
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 112
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 110
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 110
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 108
“Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial” 108
Comparative analysis of synovial inflammation after SARS-CoV-2 infection 106
Simultaneous onset of mycobacterium kansasii pulmonary infection and systemic lupus erythematosus: A case report 106
Social media as a tool for scientific updating at the time of COVID pandemic: Results from a national survey in Italy 105
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 103
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 102
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 102
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population 101
Interpretation systems for genotypic drug resistance of HIV-1 99
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study 99
Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients 99
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 95
Clinical implications of HIV-1 drug resistance in the neurological compartment 94
First description of the katG gene deletion in a Mycobacterium tuberculosis clinical isolate and its impact on the mycobacterial fitness 94
Effect of HCV infection on glucose metabolism in pregnant women with HIV receiving HAART 93
Association between Older Age and Psychiatric Symptoms in a Population of Hospitalized Patients with COVID-19 92
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 90
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 90
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 88
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry 87
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 86
Impact of SARS-CoV-2 vaccination and passive prophylaxis with tixagevimab/cilgavimab on CAR-T patients: a three-year regional experience from the Italian covid pandemic 83
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 82
Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition 81
COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes 81
[Treating HIV disease: back to the patient?] 80
Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failure. 79
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting 77
Long-acting agents for HIV infection: biological aspects, role in treatment and prevention, and patient's perspective 76
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 76
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 75
Effect of Lockdowns on Hospital Staff in a COVID Center: A Retrospective Observational Study 73
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: Data from the ICONA foundation study group, years 1997-2013 71
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials 70
Outbreaks of autochthonous Dengue in Lazio region, Italy, August to September 2023: preliminary investigation 69
Prolonged survival in HIV-associated Progressive Multifocal Leukoencephalopathy treated with Pembrolizumab: a case series on treatment and long-term follow-up 68
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 68
Cerebrospinal fluid drain infection caused by pandrug-resistant Staphylococcus epidermidis successfully treated with ceftaroline in combination with fosfomycin and vancomycin 66
Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort 65
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 64
Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data 63
Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis - results from the ICONA cohort in Italy, 2009-2022 61
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 60
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts 59
COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes 57
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 57
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis 47
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial 46
Is the rate of virological failure to cART continuing to decline in recent calendar years? 38
Treatment outcomes and relapses of pulmonary tuberculosis in Lazio, Italy, 1999-2001: a six-year follow-up study 38
A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments 16
Safety and efficacy of SARS-Cov2 neutralizing monoclonal antibodies after stem cell transplant or CAR-T cell infusion 13
Totale 9.908
Categoria #
all - tutte 45.468
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.468


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021256 0 0 0 0 0 23 34 14 67 24 77 17
2021/2022669 53 44 14 41 32 20 12 99 33 54 110 157
2022/20231.824 190 187 182 335 175 233 86 97 185 70 63 21
2023/2024929 42 198 37 52 40 167 67 36 22 61 83 124
2024/20252.069 36 52 126 102 144 95 138 92 321 192 393 378
2025/20262.816 654 202 384 594 762 220 0 0 0 0 0 0
Totale 9.908